Sign in or Register   Sign in or Register
  |  

Mouse Anti-DUX4 Monoclonal Antibody (P2B1) (CBMAB-1080-YC)

Provided herein is a mouse monoclonal antibody against Human DUX4. The antibody, clone P2B1, can be used for immunoassay techniques, such as IF, IHC-P and WB.
See all DUX4 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
P2B1
Antibody Isotype
IgG1
Application
IF, IHC-P, WB

Basic Information

Immunogen
C-terminal 76 amino acids of DUX4 with GST tag
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
>95%, as determined by SDS-PAGE analysis
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Double Homeobox 4
Introduction
Double homeobox 4 (DUX4) is located within a D4Z4 repeat array in the subtelomeric region of chromosome 4q. DUX4 has been reported to function as a transcriptional activator of paired-like homeodomain transcription factor 1 (PITX1; GeneID 5307). Contraction of the macrosatellite repeat causes autosomal dominant facioscapulohumeral muscular dystrophy (FSHD).
Entrez Gene ID
100288687
UniProt ID
Q9UBX2
Alternative Names
DUX4L
Research Area
Isoform 1:
Transcription factor that is selectively and transiently expressed in cleavage-stage embryos (PubMed:28459457).

Binds to double-stranded DNA elements with the consensus sequence 5'-TAATCTAATCA-3' (PubMed:28459457, PubMed:28459454, PubMed:29572508, PubMed:30540931, PubMed:30315230).

Binds to chromatin containing histone H3 acetylated at 'Lys-27' (H3K27ac) and promotes deacetylation of H3K27ac. In parallel, binds to chromatin that lacks histone H3 acetylation at 'Lys-27' (H3K27ac) and recruits EP300 and CREBBP to promote acetylation of histone H3 at 'Lys-27' at new sites (PubMed:26951377).

Involved in transcriptional regulation of numerous genes, primarily as transcriptional activator, but mediates also repression of a set of target genes (PubMed:17984056, PubMed:27378237, PubMed:26951377, PubMed:28459457, PubMed:28459454, PubMed:29618456, PubMed:30540931, PubMed:29572508).

Promotes expression of ZSCAN4 and KDM4E, two proteins with essential roles during early embryogenesis (PubMed:27378237, PubMed:26951377, PubMed:28459457, PubMed:29618456).

Heterologous expression in cultured embryonic stem cells mediates also transcription of HERVL retrotransposons and transcripts derived from ACRO1 and HSATII satellite repeats (PubMed:28459457).

May activate expression of PITX1 (PubMed:17984056).

May regulate microRNA (miRNA) expression (PubMed:24145033).

Inappropriate expression can inhibit myogenesis and promote apoptosis (PubMed:26951377, PubMed:28935672, PubMed:29618456).

Isoform 2:
Probably inactive as a transcriptional activator, due to the absence of the C-terminal region that is important for transcriptional activation. Can inhibit transcriptional activation mediated by isoform 1. Heterologous expression of isoform 2 has no deleterious effect on cell survival.
Biological Process
Apoptotic process Source: UniProtKB
Negative regulation of cell population proliferation Source: UniProtKB
Negative regulation of G0 to G1 transition Source: UniProtKB
Positive regulation of transcription by RNA polymerase II Source: UniProtKB
Regulation of transcription by RNA polymerase II Source: GO_Central
Cellular Location
Isoform 1: Nucleus. Actively transported through the nuclear pore complex (NPC).
Isoform 2: Nucleus
Involvement in disease
Facioscapulohumeral muscular dystrophy 1 (FSHD1):
The gene represented in this entry is involved in disease pathogenesis. The disease is caused by deletion of an integral number of units of a 3.3-kb tandem repeats, termed D4Z4 macrosatellite, located on chromosome 4q35. In unaffected subjects, the D4Z4 array consists of 11-150 repeats, while in FSHD1 patients, the array is reduced to 1-10 repeats (PubMed:19320656). DUX4 is located in D4Z4 macrosatellite which is epigenetically repressed in somatic tissues. D4Z4 chromatin relaxation in FSHD1 results in inefficient epigenetic repression of DUX4 and a variegated pattern of DUX4 protein expression in a subset of skeletal muscle nuclei. Ectopic expression of DUX4 in skeletal muscle activates the expression of stem cell and germline genes, and, when overexpressed in somatic cells, DUX4 can ultimately lead to cell death.
A degenerative muscle disease characterized by slowly progressive weakness of the muscles of the face, upper-arm, and shoulder girdle. The onset of symptoms usually occurs in the first or second decade of life. Affected individuals usually present with impairment of upper extremity elevation. This tends to be followed by facial weakness, primarily involving the orbicularis oris and orbicularis oculi muscles.

Jagannathan, S. (2022). The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 166367.

Lu-Nguyen, N., Malerba, A., Herath, S., Dickson, G., & Popplewell, L. (2021). Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model. Human Molecular Genetics, 30(15), 1398-1412.

Mocciaro, E., Runfola, V., Ghezzi, P., Pannese, M., & Gabellini, D. (2021). DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy. Cells, 10(12), 3322.

Lin, Y. K., Wu, W., Ponce, R. K., Kim, J. W., & Okimoto, R. A. (2020). Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma. Proceedings of the National Academy of Sciences, 117(34), 20776-20784.

Lim, K. R. Q., Nguyen, Q., & Yokota, T. (2020). DUX4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy. International Journal of Molecular Sciences, 21(3), 729.

Rojas, L. A., Valentine, E., Accorsi, A., Maglio, J., Shen, N., Robertson, A., ... & Wallace, O. (2020). p38α regulates expression of DUX4 in a model of facioscapulohumeral muscular dystrophy. Journal of Pharmacology and Experimental Therapeutics, 374(3), 489-498.

Okimoto, R. A., Wu, W., Nanjo, S., Olivas, V., Lin, Y. K., Ponce, R. K., ... & Bivona, T. G. (2019). CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. The Journal of clinical investigation, 129(8), 3401-3406.

Oliva, J., Galasinski, S., Richey, A., Campbell, A. E., Meyers, M. J., Modi, N., ... & Sverdrup, F. M. (2019). Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy. Journal of Pharmacology and Experimental Therapeutics, 370(2), 219-230.

Dib, C., Zakharova, V., Popova, E., Kiseleva, E., Chernyak, B., Lipinski, M., & Vassetzky, Y. S. (2019). DUX4 pathological expression: causes and consequences in cancer. Trends in cancer, 5(5), 268-271.

Dong, X., Zhang, W., Wu, H., Huang, J., Zhang, M., Wang, P., ... & Meng, G. (2018). Structural basis of DUX4/IGH-driven transactivation. Leukemia, 32(6), 1466-1476.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-DUX4 Monoclonal Antibody (P2B1)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare